Industry News
Biotechnology Industry News
AstraZeneca success torpedoes PCI’s pivotal plan, crushing stock
AstraZeneca success torpedoes PCI's pivotal plan, crushing stock ntaylor Tue, 01/25/2022 - 06:23
89bio, trying to rise from ashes of NASH failures, posts gains in disease severity, cardiovascular health in small data set
89bio, trying to rise from ashes of NASH failures, posts gains in disease severity, cardiovascular health in small data set aarmstrong Mon, 01/24/2022 - 14:51
New clinical trial organization launches with promise to conduct randomized trials at fraction of the cost
New clinical trial organization launches with promise to conduct randomized trials at fraction of the cost aarmstrong Mon, 01/24/2022 - 10:36
1b, or not 1b: FDA hits Viking with clinical hold over mix-up in phase of rare disease trial
1b, or not 1b: FDA hits Viking with clinical hold over mix-up in phase of rare disease trial ntaylor Mon, 01/24/2022 - 08:26
MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year
MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year ntaylor Mon, 01/24/2022 - 07:13
New research on tau’s role in neurodegenerative diseases like Alzheimer’s could inform new treatments
New research on tau's role in neurodegenerative diseases like Alzheimer's could inform new treatments klahucik Fri, 01/21/2022 - 13:51
Alnylam touts data replication for next-generation Onpattro in ATTR trial but analysts pour some cold water
Alnylam touts data replication for next-generation Onpattro in ATTR trial but analysts pour some cold water aarmstrong Fri, 01/21/2022 - 10:40
MD Anderson inks deal to put Chinese cancer drugs through trials, starting with a PI3K inhibitor
MD Anderson inks deal to put Chinese cancer drugs through trials, starting with a PI3K inhibitor ntaylor Fri, 01/21/2022 - 08:00
Kura exits FDA clinical hold after agreeing to mitigation measures, enabling resumption of blood cancer trial
Kura exits FDA clinical hold after agreeing to mitigation measures, enabling resumption of blood cancer trial ntaylor Fri, 01/21/2022 - 06:37
CROs embracing tech to decentralize trials and speed enrollment as regulators show support ‘with their feet’
CROs embracing tech to decentralize trials and speed enrollment as regulators show support 'with their feet' aarmstrong Thu, 01/20/2022 - 08:54
Fresh from $86M series A, Metis poaches Kala CSO to support move into the clinic
Fresh from $86M series A, Metis poaches Kala CSO to support move into the clinic ntaylor Thu, 01/20/2022 - 08:18
Bloodletting at Zymeworks as new CEO axes half of senior leaders, plans 25% reduction in headcount
Bloodletting at Zymeworks as new CEO axes half of senior leaders, plans 25% reduction in headcount ntaylor Thu, 01/20/2022 - 05:27
Fierce JPM Week: Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen’s Aduhelm
Fierce JPM Week: Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelm aarmstrong Wed, 01/19/2022 - 13:56
Fierce JPM Week: As Novartis tries to avoid ‘me-too’ meds in M&A hunt, R&D chief urges biotechs to ‘please reach out’
Fierce JPM Week: As Novartis tries to avoid 'me-too' meds in M&A hunt, R&D chief urges biotechs to 'please reach out' aarmstrong Wed, 01/19/2022 - 12:59
Charles River diving deeper into AI drug development in partnership with Valo Health
Charles River diving deeper into AI drug development in partnership with Valo Health jkeenan Wed, 01/19/2022 - 10:09
Altos bursts out of stealth with $3B, a dream team C-suite and a wildly ambitious plan to reverse disease
Altos bursts out of stealth with $3B, a dream team C-suite and a wildly ambitious plan to reverse disease ntaylor Wed, 01/19/2022 - 06:36
Barron quits GSK to take CEO post at $3B biotech startup, leaving Wood to finish what he began
Barron quits GSK to take CEO post at $3B biotech startup, leaving Wood to finish what he began ntaylor Wed, 01/19/2022 - 05:42
Eli Lilly lines up metabolic pacts with Evotec, Abbisko as it awaits diabetes med nod from FDA
Eli Lilly lines up metabolic pacts with Evotec, Abbisko as it awaits diabetes med nod from FDA klahucik Tue, 01/18/2022 - 09:07
With $825M SPAC merger, ProKidney sets stage for phase 3 trial of kidney disease cell therapy
With $825M SPAC merger, ProKidney sets stage for phase 3 trial of kidney disease cell therapy ntaylor Tue, 01/18/2022 - 08:26
Fierce JPM Week: Johnson & Johnson’s JLABS—Taming the beast, while letting it roam the world
Fierce JPM Week: Johnson & Johnson's JLABS—Taming the beast, while letting it roam the world badams Tue, 01/18/2022 - 07:38